Meeting
2023 ASCO Annual Meeting
Profile of toxicities and quality of life in long-term survivors treated with immunotherapy: A prospective cross sectional trial.
Authors
Paolo Bossi
Medical Oncology Unit, Department of Medical & Surgical Specialties, Radiological Sciences & Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy
Paolo Bossi , Maria Baronchelli , Luigi Lorini , Consiglia Paduano , Davide Smussi , Erika Stucchi , Fiorella Manfredi , Maritini Kalogerini , Giorgos Giotis , Thanos Kalligeris , Spyros Papafragkos , Kostantina Liagkou , Simona Carnio , Silvia Stragliotto , Fausto Roila , Giulia De Feo , Laura Velutti , Andrea Caglio , Marco Gunnellini , Alfredo Berruti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Quality Improvement
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6569)
DOI
10.1200/JCO.2023.41.16_suppl.6569
Abstract #
6569
Poster Bd #
61
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
The effect of the microbiome on immune checkpoint inhibitor toxicity in patients with melanoma.
First Author: Nyelia Williams
Poster
2024 ASCO Annual Meeting
Comparing rates of immune checkpoint inhibitor toxicity in different treatment settings (neoadjuvant, adjuvant, and palliative) in non-small cell lung cancer (NSCLC): A meta-analysis of phase III clinical trials.
First Author: Carolyn Moloney
Poster
2023 ASCO Annual Meeting
Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma.
First Author: Piyush Grover
Poster
2023 ASCO Annual Meeting
REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design.
First Author: Michael Seckl